| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 1033.07 Billion | USD 4147.30 Billion | 16.7% | 2023 |
According to the report published by Zion Market Research, the global Geriatric Medicines Market size was valued at USD 1033.07 Billion in 2023 and is predicted to reach USD 4147.30 Billion by the end of 2032. The market is expected to grow with a CAGR of 16.7% during the forecast period. The report analyzes the global Geriatric Medicines Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Geriatric Medicines industry.
Geriatrics is a division of medicines related to the remedial, clinical, social, and preventive aspects of ill health generally among the population over 65 years old. The majority of the geriatrics is not capable to taking their medication accurately at the planned time owing to complex psychological and medical issues. The geriatric population needs special attention and care for the rapid revival of disorder or diseases.
The general increase in the elderly population in various regions, primarily in developed and developing countries, is the main driver of the global geriatric medicines market's expansion. The mounting frequency of adults aged over 65 years that are distressed by a range of chronic conditions and the increasing prevalence of diseases such as cancer, neurological disorders, cardiovascular disorder, and rheumatoid arthritis are the few of major factors driving the growth of the geriatric medicines market. Moreover, a huge number of aged people dependent on polypharmacy are likely to have side-effects owing to the interactions of the diverse medicines. This, in turn, has augmented the need for geriatric care and thus boosting the geriatric medicines market growth.
Also, the rising occurrence medication-related issues among older adults and the urgent requirement for palliative care are the determining factors fueling the geriatric medicines market growth. Nevertheless, the dearth of wakefulness about the accessibility of geriatric care among aged patients in budding countries is a critical factor expected to hamper the market growth. Then again, the continuous progress in healthcare infrastructure in a number of countries in the developed and developing regions is anticipated to bring up exhilarating avenues for the market players.
The worldwide geriatric medicines market can be segmented based on therapeutic category, condition, and region.
The therapeutic category of the geriatric medicines market can be bifurcated into antihypertensive, analgesic, antidiabetic, statins, anticoagulant, proton pump inhibitor, antidepressant & antipsychotic, and others.
The condition segment of the geriatric medicines market can be categorized into arthritis, cardiovascular, cancer, neurological, respiratory, osteoporosis, and others.
Geographically, the worldwide geriatric medicines market can be divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa.
| Report Attributes | Report Details |
|---|---|
| Report Name | Geriatric Medicines Market |
| Market Size in 2023 | USD 1033.07 Billion |
| Market Forecast in 2032 | USD 4147.30 Billion |
| Growth Rate | CAGR of 16.7% |
| Number of Pages | 207 |
| Key Companies Covered | Boehringer Ingelheim GmbH, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Inc., Merck & Company Inc., GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., and Novartis AG |
| Segments Covered | By therapeutic category, By condition and By Region |
| Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
| Base Year | 2023 |
| Historical Year | 2018 to 2022 |
| Forecast Year | 2024 - 2032 |
| Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America is anticipated to dominate the worldwide geriatric medicines market. The market growth in this region can be attributed to the existence of a huge geriatric population, a well-developed compensation scenario, and the existence of superior healthcare facilities. Further, Asia Pacific region is also expected to grow at a rapid pace owing to the noteworthy enhancements in the healthcare facilities, the launch of numerous generic and patented drugs, the increase in disposable incomes, a rise in private & public healthcare expenditure, and the rise in a number of elderly population.
The prominent players in the worldwide geriatric medicines market include:
The Global Cardiovascular Drugs Market is segmented as follows:
By Therapeutic category
By Condition
By Region
FrequentlyAsked Questions
Geriatric medicines are drugs formulated for the health needs of elderly patients. They address age-related conditions with adjusted dosages and safety profiles.
The global geriatric medicines market is expected to be driven by the Market growth is driven by aging population, rising chronic disease prevalence, and increasing healthcare expenditure on elderly care.
According to study, the global geriatric medicines market size was worth around USD 1033.07 Billion in 2023 and is predicted to grow to around USD 4147.30 Billion By 2032.
The global geriatric medicines market is expected to grow at a Compound Annual Growth Rate (CAGR) of around CAGR 16.7% during the forecast period from 2024-2032.
The global geriatric medicines industry is projected to be challenged by Challenges include complex clinical trials, polypharmacy risks, and pricing pressures. Regulatory scrutiny and reimbursement constraints persist.
The Opportunities include rising elderly populations, chronic disease management expansion, and improved adherence solutions. Combination therapies, generics, and home-care distribution strengthen access will offer significant growth opportunities in the geriatric medicines market.
Personalized dosing and geriatric-friendly formulations; fixed-dose combinations for polypharmacy reduction; digital adherence and monitoring solutions are the emerging trends and innovations impacting the geriatric medicines market.
The global geriatric medicines market is expected to be led by North America during the forecast period.
Some of the prominent players operating in the global geriatric medicines market are; Boehringer Ingelheim GmbH, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Inc., Merck & Company Inc., GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., and Novartis AG and others.
The report explores crucial aspects of the geriatric medicines market, including a detailed discussion of existing growth factors and restraints, while also browsing future growth opportunities and challenges that impact the market.
HappyClients